A Clinical Trial to Assess the Pharmacokinetics, Safety, and Food Effect of AD-230 in Healthy Adults

A Randomized, Open-label, 2-period, 2-sequence, Crossover Study to Evaluate the Food Effect on the Safety and the Pharmacokinetics of AD-230 in Healthy Adult Volunteers

Status

Not yet recruiting

Phases

Phase 1

Study type

Interventional

Source

ClinicalTrials.gov

Registry ID

NCT07618845

Enrollment

Registered

2026-06-01

Start date

2026-05-01

Completion date

2026-07-01

Last updated

2026-06-01

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Chronic Liver Disease (CLD)

Brief summary

A clinical trial to assess the pharmacokinetics, safety, and food effect of AD-230 in healthy adults

Interventions

DRUGAD-230 (Fasted)

AD-230 1Tab., Per Oral, Fasted

DRUGAD-230 (Fed)

AD-230 1 Tab., Per Oral, Fed state

Study design

Allocation

RANDOMIZED

Intervention model

CROSSOVER

Primary purpose

TREATMENT

Masking

NONE

Eligibility

Sex/Gender

ALL

Age

19 Years to 64 Years

Healthy volunteers

Yes

Inclusion criteria

* Body mass index (BMI) between 18.5 kg/m2 and 29.9 kg/m2 at the time of screening visit * Subjects aged 19 years or older and under 65 years at the screening visit

Exclusion criteria

* Participation in another clinical study with an investigational drug within the 6 months from scheduled first administration * Other exclusions applied

Design outcomes

Primary

Measure	Time frame
Area under the plasma concentration-time curve during dosing interval (AUCt)	-24hours to 72hours
Maximum concentration of drug in plasma (Cmax)	-24hours to 72hours

Countries

South Korea

Contacts

CONTACTSarah Yoon

sryoon@addpharma.co.kr031-891-5576

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Jun 2, 2026